integrative approaches to prostate cancer treatment · 2020. 8. 11. · i’ll be covering a wide...

W E L L N E S S G U I D E | P R O S T A T E H E A LT H

By Isaac Eliaz, M.D., M.S., L.Ac.

INTEGRATIVE APPROACHES TO Prostate Cancer Treatment

One out of every six men in this country is struggling with prostate cancer at this very moment. So if you’re reading this report in

the wake of your own recent diagnosis, the first thing you should know is that you’re in very good company.

The second thing you should know is that addressing this disease in a way that minimizes side effects and maximizes your health

and longevity is possible… in fact, that’s the very reason I’ve written this report.

There’s absolutely no question that wading through your various treatment options can be confusing business—not least of all

in the case of prostate cancer, when some difficult choices will have to be made. But when you’re up against any kind of illness,

knowledge is one of your surest sources of power. And it’s my hope that once you’ve finished this report, you will be armed with

the information you need to ask the right questions—and make the right decisions—as you follow your own personal path to

recovery.

I’ll be covering a wide range of topics in the pages that follow, from necessary diagnostic tests to critical nutritional supplements.

But first, let me begin by explaining a little more about what’s involved in a truly integrative approach to healing prostate cancer.

D R . E L I A Z | W E L L N E S S G U I D E | P R O S T A T E H E A LT H | 2

What is Integrative Medicine? Integrative medicine is an approach to healthcare that draws upon various healing traditions and modalities to create a synergistic

movement towards health and away from disease.

As you’ve probably noticed, conventional treatments—especially in oncology—focus on attacking and destroying the disease.

While this approach has its merits, strictly disease-focused treatments neglect to support your overall health and vitality—which in

turn leads to further disintegration in your health.

The goal of integrative medicine, on the other hand, is to support your health and vitality while at the same time reducing disease.

Naturally, this would also be the goal of any effective integrative prostate cancer treatment.

Prostate cancer (PC) is a heterogeneous disease ranging from a physiological, “non-malignant” process, to an illness that can kill

you in months. But the choices you make in diagnosing and treating prostate cancer can add numerous confounding factors

which can alter the course of the disease. For example, biopsy may be recommended for full diagnosis, but it can also make a

less aggressive prostate cancer become more aggressive. Therefore, the basic principles in the treatment of PC are maximum

diagnosis and minimum intervention.

So what does this mean on a practical level?

THE FIRST STEP: EVALUATION

The first step in evaluating a person newly diagnosed with PC is to create a broad and extensive baseline—one that focuses on

both the health and the disease aspects. I frequently see patients that were initially evaluated by the leading institutions in this

country. And yet more often than not, these evaluations lack much of the necessary information critical to designing intelligent

treatment protocols.

UNDERSTANDING THE PATIENT

For a person to get back to optimal health, they first need to know where on the health and disease axis they are. This requires a

thorough evaluation. As a doctor, that means listening to the patient to get a feel for his health status. How well is he taking care

of himself? Does he exercise, walk, maintain a healthy diet, and use stress reduction methods? How quickly will he respond to a

health concern or health opportunity? (For example, a man notices a change in urinary frequency—does he call his doctor the

same day, or does he wait six months before reporting it?)

Another factor in evaluating is the willingness of the patient to address his condition. Does he have enough flexibility to make the

necessary changes in his life—and to follow through with them? This information is critical when I am making my assessments as

well as my recommendations.

A physician can think that a particular patient needs to walk one hour a day, alter their diet, take six different supplements, change

their job, etc… but making the above recommendations without considering if the person is able (or willing) to follow them would

be an example of doctor-driven medicine. In patient-driven medicine—which is the calling card of any good integrative doctor—

the reality of the patient’s situation will always determine the plan.

GATHERING ESSENTIAL DATA

The initial evaluation always has several components, which, when combined, will give us a better ability to assess the health and

disease status of the person.

These include:


1. A detailed history and intake

2. Thorough physical exam

3. Additional diagnostic methods (In my practice, I rely heavily on pulse diagnosis.)

4. Laboratory work

5. Imaging

6. Biopsies, if needed

Unfortunately, I won’t be able to cover all of these components in detail here.

Instead, I’ll focus on the four main issues:

blood tests, urine tests, imaging, and biopsies.


IMPORTANT BLOOD TESTS

PSA (Prostate-Specific Antigen)

Prostate-specific antigen is a protein produced by cells in your prostate gland, elevated levels of which can indicate the presence

of prostate cancer. It’s important to measure total and free levels, as well as tracking magnitude of changes and speed at which

the PSA is increasing. I could devote a full article on evaluating the PSA—but for now, remember these key points:

• Low PSA doesn’t necessarily mean a slow-growing disease.

• The rate of change is critical.

• PSA can have seasonal variations. PSADT (PSA Doubling Time) can predict oncologic and survival outcomes. Post-

treatment PSADT in patients with BRPC (Biochemically Recurrent Prostate Cancer) after RP (Radical Prostatectomy) is the

strongest determinant of metastasis-free and overall survival.

• It’s essential to evaluate the PSA in relationship to the size of the prostate. For example, a PSA of 4.5 with a prostate of

30ml is more worrisome than a PSA of 7.5 with a Prostate of 110ml (huge). That’s because a healthy prostate secretes PSA

at an average rate of 0.07ng/ml. For the 30ml patient, this natural production accounts for 2.1 out of the total score of 4.5—

only half. For the 7.5 patient, however, it accounts for all of the PSA.

• Prostatitis is quite non-specific, and will also elevate the PSA. So elevated PSA with urinary symptoms (a common

complaint in cases of prostatitis) is less worrisome than the same PSA without any complaints.

PAP (Prostate Acid Phosphatase)

This test—which measures levels of Prostatic Acid Phosphatase, an enzyme produced in your prostate—was used regularly before

PSA gained popularity, and it still plays a vital role in the initial evaluation.

The finding of a PAP elevation signifies that there is a higher risk that prostate cancer is outside the prostate and that the disease is

a more aggressive type. This is an essential component of the initial “staging” of prostate cancer. I use this information as a guide

to choosing further diagnostic tests and, ultimately, to guide my recommendations for an integrative treatment plan.

Hormonal Profile

The hormone profile is very important. For example, a patient with prostate cancer who has a high testosterone level will respond

better to treatment compared to a patient with the same disease, but lower testosterone levels.

Here are the basic lab tests that I order on all my patients with prostate cancer:

• Total Estrogens - As men age, testosterone is increasingly converted to estrogens. This tendency is compounded

by exposure to environmental toxins, xenoestrogens, and toxic heavy metals. I often see an increase in total estrogen,

estrogen to testosterone ratio, and 16-hydroxy estrogen to 2-hydroxy estrogen ratio.

These hormonal changes are significant factors in the pathogenesis of prostate cancer and contribute greatly to the

increased incidence of prostate cancer. It’s in restoring this critical hormonal balance that complementary and integrative

medicine has come to play a leading role in the prevention of prostate cancer.

• Testosterone - total and free

• Progesterone


• DHEA-S (Dehydroepiandrosterone Sulfate)

• DHT (Dihydrotestosterone)

• Prolactin - Higher levels (including high-normal) have a worse prognosis.

• CEA (Carcinoembryonic Antigen) - Cancer tends to be more aggressive when this colon cancer marker is elevated.

• IGF-1 (Insulin-like Growth Factor 1) - When elevated, this also indicates a more aggressive disease. However, I haven’t

found this one to be as useful as I hoped. It may be a laboratory detection issue.

• Thyroid Function - Thyroid function is also important, as it can indicate the speed of the individual’s metabolism.

In cancerous conditions, the body will often attempt to slow down the thyroid in an attempt to slow down the disease.

As such, the problem is not really in the thyroid—it’s merely an adaptive response of the body. For that reason, I always

exercise caution when considering thyroid support in a patient with cancer. From the perspective of health and disease, if

the condition is moving faster than the health aspect, speeding up that aspect is not a good idea. If, on the other hand, the

patient is winning their fight, speeding up can allow for more healing to be accomplished in a shorter period.

In addition:

IMPORTANT URINE TESTS

PCA3 test

PCA3 (Prostate Cancer Gene 3) is a gene-based test carried out on a urine sample. PCA3 is highly specific to prostate cancer—

and therefore, in contrast to PSA, it’s not increased by common conditions such as benign enlargement BPH (Benign Prostatic

Hyperplasia) or inflammation of the prostate (prostatitis).

There are four scenarios in which PCA3 could help in making better decisions in diagnosing and treating PC. Using this test, a

doctor can determine:

The PCA3 test has yet to be cleared or approved by the U.S. Food and Drug Administration (FDA). However, this test is available

and is being used by some of the most progressive physicians working with prostate cancer patients today.

To have this test performed in the U.S., go to http:/www.pca3.org

1. Which men with ≥ 1 negative biopsy have a high probability of a positive repeat biopsy

2. Which men with an elevated PSA level (between 2.5 and 10 ng/mL) or a low PSA level but a suspicious DRE (Digital

Rectal Exam) have a high probability of a positive first biopsy

3. Which men with PC (prostate cancer) have a high probability of significant PC

4. Which men with PC have a high probability of disease progression on watchful waiting


IMAGING TESTS

A good baseline requires useful imaging. Unfortunately, an ultrasound taken in the average urologist’s office is unacceptable.

Some reliable state-of-the-art imaging techniques include:

THE QUESTION OF BIOPSY

Biopsies are the gold standard for confirmation of PC. So why even write about them?

Well, biopsies are over-performed. When are they needed? The fundamental question I ask when it comes to biopsies is: Will the

biopsy make a difference in the treatment plan? Individual patients with localized disease are adamant about following their imag-

ing and staying on watchful waiting—and for them, the biopsies will make no difference whatsoever.

Biopsies provide essential information on the grade of the disease, the Gleason score, and how extensively the disease has spread

on the local level. (For more information about cancer grading and Gleason scores visit here.

Knowing the level of aggressiveness of cancer and whether it is localized or has extended beyond the prostate gland itself are

crucial pieces of information for formulating an effective integrative treatment strategy.

However, biopsies have the following disadvantages:

Color Doppler flow ultrasound

This is an excellent and cost-effective imaging method. The limitation is that at present, very few doctors know how to do

it well. I am fortunate to have one of the best imagers in the country nearby at the University of California, San Francisco

(UCSF).

MR-S (Magnetic Resonance Imaging-Spectroscopy) or Endorectal MRI-S

Also known as magnetic imaging with spectroscopy, this is an advancement in imaging where two modalities are used and

compared. It’s used to help determine the probability of organ-confined disease, or to see if cancer has spread to seminal

vesicles or regional lymph nodes.

Bone Scan, PET/CT (Positron Emission Tomography/Computed Tomography (PET/CT) ) imaging, and PSMA (Prostate-

Specific Membrane Antigen)

The test may be ordered for the initial staging of prostate cancer if aggressive disease is suspected from the biopsy report.

A PET Scan can also help detect bone and soft tissue metastasis.

• Side effects, including long term pain, possible infections, and disturbance in urination.

• The spread of disease. Although there are no good studies to confirm this point, we do know that for patients with

negative RT-PCR (Real Time-Polymerase Chain Reaction), meaning, no PC cells are detected systemically by gene

amplification, half will turn positive after radical prostatectomy. Logically speaking, multiple injuries to the tissue (in this

case, caused by 6 to 18 biopsies) will increase inflammation and angiogenesis, both being significant contributors toward

metastasis.

• False-negative is another concern. False negatives can range from 20 to 40 percent, depending on how many biopsies

are done, what imaging techniques are used, and who is doing them.

https://www.pcf.org/about-prostate-cancer/diagnosis-staging-prostate-cancer/gleason-score-isup-grade/


If you can get good imaging routinely, the PSA is low, and the disease is localized to a small part of the prostate, follow-up with-

out biopsy is a viable choice—one that I think will become more popular over time. PCA3 can also prevent unnecessary biopsies,

as I mentioned before. But of course, making this decision is easier if you have all the laboratory data and know-how to interpret it.

If you are undergoing biopsies, the most important supplement for you to take is modified citrus pectin—at a dosage of 15 grams

per day for a week before biopsies, and for the three to four weeks after. This can reduce the chance of cancer spreading due to

the procedure.

Androgen Deprivation Therapy

The goal of androgen deprivation therapy is to suppress levels of male hormones in your body, as they are known to stimulate

the growth of prostate cancer cells. It’s a form of systemic treatment for men who are unwilling or unable to undergo surgery or

radiation.

Combined hormonal therapy—or the use of more than one hormone-modulating drug—can yield positive results when used ap-

propriately over a long period. However, monotherapy—the use of a single agent, such as Bicalutamide (Casodex®) without sup-

pression of testosterone—offers the best quality of life. I prefer this method in cases of less aggressive disease, where the quality

of life and sexual function are a major consideration.

CONVENTIONAL TREATMENTS

Once your diagnosis has been established, it’s time to consider your choices in terms of treatment, the best course of which will

ultimately depend on your situation. Your options include:

COMPLEMENTARY TREATMENTS

Diet

Any beneficial integrative program for prostate cancer will always begin with dietary modification. These are some of the most

critical changes you can make, and they can have a considerable impact on your health in the long term.

The first modification you should consider is the elimination of red meats. Meat contains high amounts of arachidonic acid, and

Localized treatments

• External radiation (3D conformal) therapy. This has been improved as IMRT (Intensity Modulated Radiation Therapy),

where the intensity can be modified based on the location—delivering more radiation to the tumor and less to the

surrounding tissue.

• Seed implants—another form of radiation in which radioactive seeds are implanted into the prostate gland to concentrate

the activity while reducing damage to surrounding tissue.

• Radical prostatectomy or prostate removal is the last on my list as it tends to result in a high number of undesirable

effects—including erectile dysfunction and urinary incontinence.


some by-products of arachidonic acid have promoted prostate cancer in animals. Also, well-done and cured meats (such as ba-

con, salami, and ham) can promote prostate cancer—so you’ll want to limit your consumption of these as well.

Fish, high in omega-3 fatty acids, on the other hand—think wild Atlantic salmon, for example—have shown to be beneficial for

prostate cancer patients. With that said, you should be wary of fish that are also high in mercury (such as swordfish and tuna).

It’s always wise for you to keep your mercury levels as low as possible, and it’s especially important when you’re battling prostate

cancer—or any disease for that matter.

Finally, several servings of cruciferous vegetables a day—such as cabbage, Brussels sprouts, broccoli, and cauliflower—can help to

fight prostate cancer and reduce your risk of this disease, In test tube and animal studies, these foods have been shown to have

potent anticancer activity—likely due to several of their active compounds, including indole-3-carbinol, 5 glucaric acid (calcium D-

glucarate), and sulforaphane. But protective effects of cruciferous vegetables are also thought to be due to their high concentra-

tion of the carotenoids lutein and zeaxanthin, as well as their stimulatory effects on the breakdown of environmental carcinogens

associated with prostate cancer.

Whatever their primary mode of action may be, the value of “eating your vegetables” has been borne out in many clinical stud-

ies—with some very impressive results. A recent preliminary study of men newly diagnosed with prostate cancer showed a 41

percent decreased risk of prostate cancer among those men eating three or more servings of cruciferous vegetables per week, as

compared with those eating less than one serving per week.

Critical Supplements

In addition to dietary changes, you’ll also find that you have a number of supplements to choose from as part of a complimentary

program—and in my clinical experience, they can have an extraordinarily powerful effect in the fight against prostate cancer.

Based on the latest scientific research, many different nutrients have shown promise in the prevention and control of prostate

cancer. Combining these nutrients in sufficient amounts allows cancer to be attacked from all sides at once—both inhibiting can-

cer and promoting long-lasting health. They can be used at all stages and in conjunction with all conventional treatment

protocols.

These nutrients can be divided according to their beneficial principles:

1. Anti-tumor

2. Prevention of cancer metastasis

3. Detoxification, liver support

4. Hormonal modulation

5. Anti-microbial

6. Anti-inflammatory and antioxidant

7. Anti-angiogenesis

8. Immune enhancement


Many supplements can be used, some of which I detail later, but here is a highlight on two of the most important: modified citrus

pectin (for prevention of metastasis) and medicinal mushrooms (for immune enhancement).

Modified Citrus Pectin

Clinical studies show that a specific form of Modified Citrus Pectin (MCP), derived from the pith of citrus fruit peels, is essential

in the treatment of prostate cancer. It directly attacks cancer, thereby reducing the disease—but at the same time, it has properties

that enhance the overall health of the individual, making it a powerful anti-cancer nutrient. Let me take a moment to explain how

it can do this.

Cancer cells are different from healthy cells in a number of important ways. First and foremost, they have lost control of the “cell

cycle”—a natural cycle that controls when cells live, when they divide, and when they die. Cancer, by definition, grows out of

control without any of the usual checks and balances. As such, many cancer-killing herbs, nutrients, and drugs function by getting

cancer cells to enter back into the cell cycle and die a natural death.

Another significant difference that cancer cells have is they “look” different from healthy cells. All cells have different molecules on

their surface, and these molecules allow the cells to communicate with each other and their environment. These molecules have

multiple functions:

Cancer cells can have several distinct qualities that separate them from healthy cells. They may have more of one type or less of

another—or they have markers on their surface that clearly state, “Hey—I’m an out-of-control cancer cell!” These changes on the

surface of cancer cells allow white blood cells to recognize them as cancerous and kill them.

One type of molecule that is overexpressed in many types of cancer, and that drives cancer growth through numerous mecha-

nisms, is called galectin-3. Galectin-3 molecules help cancer grow, spread, and evade the immune system, through multiple pro-

cancer actions. First, galectin-3 stimulates the growth of new blood vessels—a process called angiogenesis. This allows cancer to

get the blood flow and nutrients it needs to grow out of control.

Second, galectin-3 allows cells that break off from the primary tumor to aggregate or clump together in the bloodstream—this

allows the cancer cells to move to a new site in the body, i.e. metastasize. Galectin-3 also shields cancer from the immune sys-

tem, and creates an inflammatory pro-cancer environment for the disease to thrive. For these reasons, galectin-3 has earned the

moniker, “Guardian of the tumor microenvironment.”

Importantly, this specific form of Modified Citrus Pectin is the only available agent shown to enter the circulation to bind and

block galectin-3 molecules—which means the cancer cells can’t spread and grow. MCP is repeatedly shown to halt the growth

and spread of aggressive cancers, enhance conventional and complementary cancer treatments, and reverse the course of this

deadly disease—primarily due to its unique ability to disrupt the pro-cancer actions of deadly galectin-3. Because of its multiple

anti-cancer actions, this researched form of MCP has become known internationally as a powerful natural cancer therapy—most

• They are receptors for neurotransmitters or hormones

• They are markers that identify what type of cell it is

• They act as “hands” that let the cell stick in place or move around

https://www.dreliaz.org/formulas/modified-citrus-pectin/https://www.dreliaz.org/formulas/modified-citrus-pectin/

D R . E L I A Z | W E L L N E S S G U I D E | P R O S T A T E H E A LT H | 1 0

notably, in prostate cancer as shown in a growing number of clinical studies.

Published Clinical Data: MCP Halts Prostate Cancer

The most recent published clinical study involves a groundbreaking clinical trial on men with BRPC. Initial results on 46 patients

after 6 months of MCP treatment were originally presented at the ASCO (American Society of Clinical Oncology) annual meeting

in Chicago, IL, in June, 2019.

These results demonstrated the ability of MCP to slow PSADT is an important metric that measures recurrent prostate cancer

growth in patients whose prostate has been treated with surgery and/or radiation. Of the 46 patients enrolled at the six-month

evaluation, 76% (35 patients) showed reduction in disease progression, 70% (32 patients) had an improvement (increase) of

PSADT, and all had no metastases on scans at 6 mos. Those that did not progress at 6 months, were treated for subsequent 12

months to look at long term effects.

Updated results from this study, following an additional 12 months of treatment with MCP, were published in European Urology

Supplements and presented at the 11th European Multidisciplinary Congress on Urological Cancers—EMUC19, in Vienna, Austria,

November 2019. This extended arm of the study followed the 31 patients who completed the first six months without progres-

sion, to evaluate the long-term effects of MCP treatment (5 grams/three times day). These updated results showed that Sixty

five% (20 patients) had long term (18 mos) stable PSA and PSADT with negative scans at 18 mos. 50% of subjects had a lower PSA,

or PSADT lengthening at 18 months, compared to their baseline at the start. Currently, the 60 patients planned for the study have

completed the initial 6 months with promising results, and all the patients who showed benefit are continuing for an additional 12

months. There was no treatment interruption due to adverse effects.)

Early MCP Research in Prostate Cancer

Early research on prostate cancer showed that oral administration of MCP to rodents resulted in a dramatic reduction in prostate

cancer metastasis to the lungs. More recent research from this same group of scientists has extended the protection of MCP to

breast and colon cancer and has shown that MCP blocks the growth of primary tumors and the formation of new blood vessels.

A commercially available form of modified citrus pectin was developed in response to the positive results of the animal studies

and was tested in men with prostate cancer. A pilot trial using MCP at 15 grams/day, and a subsequent phase II trial both showed

that MCP slows the progression of prostate cancer as evidenced by a reduction in the rate of PSA rise. The pilot phase II trial

involved men where primary conventional treatment was initially successful, but subsequently, their PSA began to climb again,

representing cancer recurrence. This time, 70 percent of the trial participants showed an extension of their PSADT.

Recent advances have introduced a new, more potent form of this compound—which has since demonstrated even more com-

pelling results among a group of late-stage cancer patients. In late 2007, researchers at Albert-Ludwigs University in Freiburg, Ger-

many, enrolled 49 patients, each with advanced state solid tumors of varying types—colon cancer, prostate cancer, breast cancer,

kidney cancer, lung cancer, cervical cancer, liver cancer, and pancreatic cancer, among others. Each patient had completed

conventional treatments, including surgery, chemotherapy, and radiation without success—nearly 90 percent of the cancers had

metastasized.

During the trial, patients were administered 5 grams of MCP orally, three times a day. They would later be evaluated for clinical


benefit—including pain reduction, improved physical functioning, increased appetite and sleep, and reduced fatigue. At just eight

weeks, the results were already overwhelmingly positive, with 20.7 percent of the patients showing an overall clinical benefit

response and stabilization of disease.

By the conclusion of the study, response rates continued to improve, with a majority of the patients showing an improved quality

of life and pain reduction. And perhaps most remarkably, one patient with metastasized prostate cancer demonstrated a 50 per-

cent decrease in PSA levels at 16 weeks, accompanied by a significant increase in clinical benefit.

More recent research—published in the journal Integrative Cancer Therapies, and performed in conjunction with Columbia

University—points to the potential mechanism of this action. Results indicate that MCP can inhibit cell proliferation and apoptosis

in prostate cancer cell lines (including androgen-dependent and androgen-independent cells), induce apoptosis by the cleavage

of caspase-3 (a protein involved in the activation cascade of caspases responsible for programed cell death, AKA apoptosis), and

inhibit cell proliferation by reducing MAP (Mitogen-Activated Protein) kinase signaling pathway (which promotes cell growth, pro-

liferation, and survival). This ability to induce apoptosis in androgen-independent prostate cancer cell lines is especially significant,

as it is the more aggressive form of cancer that can metastasize and lead to death. Any help in slowing down the progression of

this cancer has a direct effect on prolonging a patient’s life.

MCP: Safe Heavy Metal Chelator

Another unique quality attributed to MCP is its effectiveness as a chelating agent. Heavy metals, in conjunction with the abun-

dance of environmental toxins and xenoestrogens (estrogen-mimicking compounds), constitute a dangerous insult to the body

through DNA damage, hormonal dysregulation, immune suppression, oxidative stress, and hyper-inflammation. And they are of

particular concern in prostate cancer.

The chelation properties of MCP have been confirmed in several clinical trials—showing that in healthy individuals, MCP can safely

and gently increase the urinary excretion of toxic metals such as mercury, cadmium, arsenic, and lead. These results have been

paired with significant improvement in various clinical symptoms, suggesting that MCP’s ability to remove heavy metals and envi-

ronmental toxins on an ongoing basis may be of great benefit to cancer patients.

It must be noted that there is only one form of MCP that has been validated in human clinical trials. This is important since not all

MCPs are the same—and no other product on the market matches the chemical specifications of the MCP used in human clinical

trials. If the molecular weight of the MCP is too high, it can’t be absorbed into the bloodstream—if it is too low, it won’t effectively

block all the galectin sites. Another property, the degree of esterification, must be below 5% to get optimal binding.

If you want to achieve the effects seen in the growing number of published studies, you must use the same preparation, with ap-

propriate doses according to your needs (see Table 1, below). I also invite you to read the comprehensive report that I’ve com-

piled on MCP, which covers the extensive research on this incredible compound.

It’s available for free at my website www.dreliaz.org

https://www.dreliaz.org/wellness/modified-citrus-pectin-guide-page/


MCP Application Use (take on an empty stomach)

Active Cancer 15 grams/day (5 grams, 3 times a day)

Biopsy 15 grams/day (5 grams, 3 times a day)Take one week before procedure and two weeks after.

Heavy Metal Chelation High body burden levels: 15 grams/day (5 grams, 3 times a day)

Lower levels: 15 grams/day for 5 days a month, 5 grams/day

the rest of the month

Cancer Prevention 5 grams/day ongoing

TABLE 1: THE USE OF MODIFIED CITRUS PECTIN

Medicinal Mushrooms

Medicinal mushrooms have been well researched for their anti-tumor and immune-stimulating effects and are essential for the

maintenance of vitality. Simply put, they support your body’s natural immune functions. In an ideal world, all aberrant cells in the

body would be identified and destroyed by natural killer cells or other circulating immune cells. But stress, exposure to toxins, and

other health imbalances can reduce your immune system’s ability to work optimally.

Medicinal mushrooms, on the other hand, regulate your immune system to perform at its highest potential. They are important

for maintaining long term health in this modern world and are even more critical for individuals who have cancer.

If you are new to using mushrooms, I recommend you start with a “priming” dose for one to two months. This dose should be

two or three times the maintenance level. (I also suggest that you double your maintenance dose during the first two weeks of

the spring and autumn.) After this, you can drop to the maintenance dose, which is typically the suggested dose.

It is important to take medicinal mushrooms on a long-term basis, as some of their benefits require an extended time of con-

sumption. For optimal immune and anti-cancer support, I recommend supplementing with a researched mushroom formula

containing a combination of mushrooms that are cultivated on a blend of immune-enhancing herbs. This revolutionary growth

method works to fortify the mushrooms with additional health benefits, and results in optimal immune protection.

Other Nutrients

As you can see in Table 2 (which covers some, but not all, of the nutrients that can be used against prostate cancer), many nutri-

ents and herbs have multiple functions. For example, Curcumin has direct anti-tumor properties, helps with hormonal modulation

and liver detoxification, and stabilizes the P-53 chromosome. One of the many strengths of nutritional and herbal therapies is the

ability to combine nutrients that have similar properties to get a more substantial, synergistic effect.

https://www.dreliaz.org/formulas/medicinal-mushrooms/


Nutrient or Herb General Use (Total amounts per day)

Highlighted Properties

Modified Citrus Pectin 15 grams/day Anti-tumor Prevents metastasis Anti-angiogenicToxic metal chelation

Medicinal mushrooms 4 – 12 grams/day Immune Enhancement Detoxification/Liver Support

Curcumin (Turmeric root extract 95% curcuminoids)

1,500-4,500 mg/day

Cytotoxic/Anti-Tumor Hormonal modulation Detoxification/Liver Support

Saw Palmetto berry extract Pygeum bark extract

100-600 mg/day

Cytotoxic/Anti-Tumor Hormonal Modulation Anti-inflammatory

Lycopene 10-30 mg/day Cytotoxic/Anti-Tumor Antioxidant

Artemisinin 200 -1,200 mg/day Cytotoxic/Anti-Tumor, use carefully- can weaken digestion

Selenium 200 mcg-3,600 mcg/day (depending on length of application)

Cytotoxic/Anti-Tumor Antioxidant

Thymic protein A As directed Immune enhancement

Stinging nettles root 150-400 mg/day Immune enhancement

Soy isoflavones 100- 1,000 mg/day Anti-angiogenic bone protection prevents metastasis

I3C (Indole-3-Carbinol) 50-300 mg/day Hormonal modulation

DIM (Diindolylmethane) 50-300 mg/day Hormonal modulation

Garlic Varies Anti-microbial

Cayenne Varies Anti-inflammatory

Green tea extract 50-500 mg/day Antioxidant Hormonal Modulation

Vitamin D-3 1,000 IU- 6,000 IU/dayMonitor kidney function with high doses

Promotes cell differentiation

Zinc 30 to 50 mg/day Antioxidant Hormonal Modulation

Vitamin E 400 to 1,200 IU/day Antioxidant

Vitamin C 1,000 to 6,000 mg/day AntioxidantOther multiple functions

Quercetin 250-2,000 mg a day AntioxidantAnti-inflammatory Reduces drug resistance

Conjugated linoleic acid (CLA)

3,000 mg/day Cytotoxic Promotes cell differentiation

Resveratrol from red grape extract (Vitus vinifera) or Polygonum cuspidatum root extract

20-200 mg/day Antioxidant

Broccoli extract 22:1 (Brassica oleracea)

50-200 mg/day Antioxidant Anti-inflammatory

Alpha lipoic acid 100-400 mg/day Antioxidant

Pomegranate 100-500 mg/day Antioxidant Anti-inflammatory

TABLE 2: SELECTED VALUABLE NUTRIENTS FOR TREATING PROSTATE CANCER

The disadvantage of having so many options, of course, is that patients may end up taking a vast number of pills, or the dosing

regimen can be too confusing.

To simplify things, I recommend using nutritional blends that are formulated to encompass many different therapeutic aspects.

These blends often use lower amounts of individual ingredients and work synergistically to produce a more substantial effect

than the recommended higher dose of a single ingredient in the table above.


With prostate cancer patients, I use a researched formula that incorporates many of these ingredients. This formula, which is

shown to work synergistically in combination with MCP, forms the foundation of a comprehensive protocol against prostate can-

cer. From this foundation, I’ll add medicinal mushrooms and other nutrients (or more of specific herbs or nutrients) as warranted

by the patient’s health and disease status.

This researched formula, ProstaCaid™ (PC), inhibits proliferation of highly invasive human hormone refractory (independent)

prostate cancer cells (PC-3), and modulates expression of prostate cancer-related biomarker genes. In addition, PC also suppress-

es invasive behavior of PC-3 cells by the inhibition of cell adhesion, migration and invasion. These results came from an experi-

ment done in the confines of a laboratory dish.

Another study examined PC inside a living organism, which is more relevant to human beings. This study found that PC does not

show signs of toxicity, and its oral application has significant anticancer activity in vivo.

Another study examined men with lower urinary tract symptoms (LUTS) who were taking PC, and found statistically significant

improvements in their LUTS scores, based on their recalled prior symptoms.

I also use other therapeutic modalities such as acupuncture, infrared saunas, lifestyle and diet recommendations, bodywork, IV

therapies, and body-mind medicine. The protocol is further modified to accommodate the use of conventional treatment.

Some supplements are specifically used to prevent or counteract the side effects of conventional therapies. A good example is

preventing osteoporosis in patients undergoing hormonal therapy and preventing clots in patients after procedures, or in men

receiving estrogenic treatments.

Whatever the side effect or concern, there’s almost always an integrative method available to counteract it.

Ultimately, when addressing prostate cancer in a holistic, integrative way, it’s essential to combine a number of beneficial thera-

peutic principles and modalities—and to employ protocols that honor the basic principles of health and disease. As my clinical

experience has repeatedly demonstrated to me, integrative medicine can be of infinite value to you in your fight against prostate

cancer—whatever its stage, and whatever other conventional treatments you may choose.

https://www.dreliaz.org/formulas/prostate-health-formula/


REFERENCES AND RESEARCH

Awad AB, Fink CS. Phytosterols as anticancer dietary components: evidence and mechanism of action. J Nutr 130(9): 2127-30, 2000.

Awad, AB, Fink CS, et al. In vitro and in vivo (SCID mice) effects of phytosterols on the growth and dissemination of human prostate cancer PC-3 cells.”Eur J Cancer Prev 10(6): 507-13, 2001.

Awad A.B, Y. Gan Y, et al. Effect of beta-sitosterol, a plant sterol, on growth, protein phosphatase 2A, and phospholipase D in LNCaP cells. Nutr Cancer 36(1): 74-8, 2000.

Azemar M, Hildenbrand B, Haering B, ManfredE. Heim, ME, Unger, C. Clinical benefit in patientswith advanced solid tumors treated with modi-fied citrus pectin: a prospective pilot study. Clini-cal Medicine: Oncology 2007:1 73-80.

Baldus SE, Zirbes TK, et al. Increased galectin-3 expression in gastric cancer: correlations with histopathological subtypes, galactosylated anti-gens and tumor cell proliferation. Tumour Biol. 21(5): 258-66, 2000.

Boileau TW, Liao Z, Kim S, Lemeshow S, Erdman JW Jr, Clinton SK. Prostate carcinogenesis in N-methyl-N-nitrosourea (NMU)-testosterone-treated rats fed tomato powder, lycopene, or energy-restricted diets. J Natl Cancer Inst.5;95(21):1578-86, 2003. Bresalier RS, Mazurek N, et al. Metastasis of human colon cancer is altered by modifying expression of the beta-galactoside-binding pro-tein galectin 3.”Gastroenterology 115(2): 287-96, 1998.

Bresalier RS, Yan PS, et al. Expression of the en-dogenous galactose-binding protein galectin-3 correlates with the malignant potential of tumors in the central nervous system. Cancer 80(4): 776-87, 1997.

Chen HH, Zhou HJ, et al. Inhibition of human cancer cell line growth and human umbilical vein endothelial cell angiogenesis by artemisinin derivatives in vitro. Pharmacol Res 48(3): 231-6, 2003.

Cohen JH, Kristal AR, Stanford JL. Fruit and vegetable intakes and prostate cancer risk. J Natl Cancer Inst 92(1):61–8, 2000. Deeb D, Xu YX, et al. Curcumin (Diferuloyl-Methane) Enhances Tu-mor Necrosis Factor-related Apoptosis-inducingLigand-induced Apoptosis in LNCaP Prostate Cancer Cells. Mol Cancer Ther 2(1): 95-103, 2003.

Deliliers GL, Servida F, et al. Effect of inositol hexaphosphate (IP(6)) on human normal and leukaemic haematopoietic cells. Br J Haematol 117(3): 577-87, 2002.

Dong Y, Zhang H, et al. Delineation of the Molecular Basis for Selenium-induced Growth Arrest in Human Prostate Cancer Cells by Oligo-nucleotide Array. Cancer Res 63(1): 52-9, 2003.

Dresler, H, Keizman D, et al. Long term effect of PectaSol-C modified citrus pectin treatment in non-metastatic biochemically relapsed prostate cancer patients: Results of a prospective phase II study. European Urology Supplements, Volume 18, Issue 11, e3467

Duffield-Lillico A J, Dalkin BL, et al. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU Int 91(7): 608-612, 2003.

Eliaz I,D. Rode, D. The effect of modified citrus pectin on the urinary excretion of toxic ele-ments. Fifth Annual Conference of Environmen-tal Health Scientists: Nutritional Toxicology and Metabolomics, University of California, Davis. 2003.

Eliaz I, Hotchkiss AT, Fishman ML, Rode D. The effect of modified citrus pectin on urinary excre-tion of toxic elements.Phytother Res. Oct;20(10):859-64, 2006.

Eliaz I, Weil E, Wilk B. Integrative medicine and the role of modified citrus pectin/alginates in heavy metal chelation and detoxification—five case reports.”Forsch Komplement Med. 2007 Dec;14(6):358-64, 2007.

Eliaz I, Weil E, Wilk B. Improvements in Self-reported Lower Urinary Tract Symptoms With Prostate Health Supplement. Altern Ther Health Med. Sep;24(5):26-32. 2018

Finkelstein MP, Aynehchi S, et al. Chemosensiti-zation of carmustine with maitake beta-glucan on androgen-independent prostatic cancer cells: involvement of glyoxalase I. J Altern Comple-ment Med 8(5): 573-80, 2002.

Frydoonfar HR, McGrath DR, et al. The effect of indole-3-carbinol and sulforaphane on a prostate cancer cell line. ANZ J Surg73(3): 154-6, 2003.

Fullerton SA, Samadi AA, et al. Induction of apop-tosis in human prostatic cancer cells with beta-glucan (Maitake mushroom polysaccharide). Mol Urol 4(1): 7-13, 2000.

Guess B, Jennrich R, et al. Using splines to detect changes in PSA doubling times. Prostate 54(2): 88-94, 2003.

Guess, B, Scholz M, et al. Modified Citrus Pectin

(MCP) Increases the Prostate Specific Antigen Doubling Time in Men with Prostate Cancer: A Phase II Clinical Trial. Prostate Cancer Prostatic Dis. 6(4):301-4, 2003, 2003.

Guzey M, Kitada S, et al. Apoptosis induction by 1alpha,25-dihydroxyvitamin D3 in prostate can-cer. Mol Cancer Ther 1(9): 667-77, 2002.

Hsu D K, Dowling CA, et al. Galectin-3 expres-sion is induced in cirrhotic liver and hepatocel-lular carcinoma. Int J Cancer81(4): 519-26, 1999.

Jiang J, Eliaz I, Sliva D. Synergistic and addi-tive effects of modified citrus pectin with two novel poly botanical compounds, in the sup-pression of invasive behavior of human breast and prostate cancer cells. Integr Cancer Ther. doi:10.1177/1534735412442369, 2012.

Jiang J, Loganathan J, Eliaz I, Terry C, Sandusky G.E., Sliva D. ProstaCaid inhibits tumor growth in a xenograft model of human prostate cancer. Int J Oncol. May;40(5): 1675-1682, 2012.

Jiang J, Isaac E, and Sliva D. Suppression of growth and invasive behavior of human prostate cancer cells by ProstaCaid: Mechanism of activ-ity. Intern. J Oncol. Jun;38(6):1675-82, 2011.

Jenkins DJ, Kendall CW, et al. Soy consumption and phytoestrogens: effect on serum prostate specific antigen when blood lipids and oxidized low-density lipoprotein are reduced in hyperlip-idemic men. J Urol 169(2): 507-11, 2003.

Kelly WK, Scher HI, et al. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol 11(4): 607-15, 1993.

Kiexman D, Frenkel MA, et al. Effect of pectasol-c modified citrus pectin (P-MCP) treatment (tx) on PSA dynamics in non- metastatic biochemi-cally relapsed prostate cancer (BRPC) patients (pts): Primary outcome analysis of a prospective phase II study. J Clin Oncol 37, 2019 (suppl; abstr e16609)

Kim L, Rao AV, et al. Effect of Lycopene on Pros-tate LNCaP Cancer Cells in Culture. J Med Food 5(4): 181-7, 2002.

Kristal A R, Lampe JW. Brassica vegetables and prostate cancer risk: a review of the epidemio-logical evidence. Nutr Cancer42(1): 1-9, 2002.

Kucuk O, Sarkar FH, et al. Phase II randomized clinical trial of lycopene supplementation before radical prostatectomy. Cancer Epidemiol Bio-markers Prev 10(8): 861-8, 2001.


REFERENCES AND RESEARCH

Kune GA. Eating fish protects against some cancers: epidemiological and experimental evidence for a hypothesis. J Nutr Med1:139–44 [review], 1990.

Lai H, Singh NP.Selective cancer cell cytotoxicity from exposure to dihydroartemisinin and holo-transferrin. Cancer Lett 91(1): 41-6, 1995.

Lee MM, Gomez SL, et al. Soy and isoflavone consumption in relation to prostate cancer risk in china. Cancer Epidemiol Biomarkers Prev 12(7): 665-8, 2003. Lee WR, Hanks GE, et al. Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: clinical observations. J Clin Oncol 15(1): 230-8, 1997.

Leitzmann MF, Stampfer MJ, et al. Zinc supple-ment use and risk of prostate cancer. J Natl Can-cer Inst 95(13): 1004-7, 2003. Marks LS, Fradet Y, et al. PCA3 Molecular Urine Assay for prostate cancer in men undergoing repeat biopsy. Urol-ogy 69:532-535, 2007.

Liu WK, Xu SX, et al. Anti-proliferative effect of ginseng saponins on human prostate cancer cell line. Life Sci 67(11): 1297-306, 2000.

Miyazaki J, Hokari R, et al. Increased expression of galectin-3 in primary gastric cancer and the metastatic lymph nodes. Oncol Rep 9(6): 1307-12, 2002.

Moon BK, Lee YJ, et al. Galectin-3 protects hu-man breast carcinoma cells against nitric oxide-induced apoptosis: implication of galectin-3 function during metastasis. Am J Pathol 159(3): 1055-60, 2001.

Moore JC, Lai H, et al. Oral administration of dihydroartemisinin and ferrous sulfate retarded implanted fibrosarcoma growth in the rat. Can-cer Lett 98(1): 83-7, 1995.

Nachshon-Kedmi M, Yannai S, et al. Indole-3-carbinol and 3,3’-diindolylmethane induce apoptosis in human prostate cancer cells. Food Chem Toxicol 41(6): 745-52, 2003.

Nakamura M, Inufusa H, et al. Involvement of galectin-3 expression in colorectal cancer progression and metastasis. Int J Oncol 15(1): 143-8, 1999.

Nangia-Makker P, Hogan V, et al. Inhibition of hu-man cancer cell growth and metastasis in nude mice by oral intake of modified citrus pectin. J Natl Cancer Inst 94(24): 1854-62, 2002.

Nangia-Makker P, Honjo Y, et al. Galectin-3 induces endothelial cell morphogenesis and an-

giogenesis. Am J Pathol 156(3): 899-909, 2000.

Norrish AE, Ferguson LR, Knize MG, et al. Heterocyclic amine content of cooked meat and risk of prostate cancer. J Natl Cancer Inst 91:2038–44, 1999.

Palombo JD, Ganguly A, et al. The antiprolif-erative effects of biologically active isomers of conjugated linoleic acid on human colorectal and prostatic cancer cells. Cancer Lett 177(2): 163-72, 2002.

Pienta KJ, Naik H, et al. Inhibition of spontaneous metastasis in a rat prostate cancer model by oral administration of modified citrus pectin. J Natl Cancer Inst 87(5): 348-53, 1995.

Platt D, Raz A .Modulation of the lung coloniza-tion of B16-F1 melanoma cells by citrus pectin. J Natl Cancer Inst 84(6): 438-42, 1992.

Ramachandran, C., Wilk, B.J., Hotchkiss, A., Chau, H., Eliaz, I., Melnick, S.J. Activation of human T-helper/inducer cell, T-cytotoxic cell, B-cell, and natural killer (NK)-cells and induction of natural killer cell activity against K562 chronic myeloid leukemia cells with modified citrus pec-tin. BMC Complem. Altern. Med. 11:59, 2011.

Ramachandran C, Wilk B, Melnick SJ, Eliaz I. Synergistic Antioxidant and Anti-Inflammatory Effects between Modified Citrus Pectin and Honokiol. Evid Based Complement Alternat Med. 2017;2017:8379843.

Rose DP, Connolley JM. Omega-3 fatty acids as cancer chemopreventive agents. Pharmacol Ther 83:217–44, 1999.

Santa María Margalef A, Paciucci Barzanti R, Reventós Puigjaner J, Morote Robles J, Thom-son Okatsu TM. [Antimitogenic effect of Pygeum africanum extracts on human prostatic cancer cell lines and explants from benign prostatic hyperplasia]. Arch Esp Urol. 56(4):369-78, 2003.

Sartor CI, Strawderman, MH, et al. Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy.Int J Radiat Oncol Biol Phys 38(5): 941-7, 1997.

Saxe GA, Hebert JR, et al. Can diet in conjunc-tion with stress reduction affect the rate of increase in prostate specific antigen after bio-chemical recurrence of prostate cancer? J Urol 166(6): 2202-7, 2001. Schuurman AG, van den Brandt PA, Dorant E, Goldohm RA, Animal products, calcium and pro-tein and prostate cancer risk in the Netherlands Cohort Study. Br J Cancer 80:1107–13, 1999.

Sharma G, Singh RP, Agarwal R. Growth

inhibitory and apoptotic effects of inositol hexaphosphate in transgenic adenocarcinoma of mouse prostate (TRAMP-C1) cells. Int J Oncol. 23(5):1413-8, 2003.

Singh, NP, Lai H. Selective toxicity of dihydroarte-misinin and holotransferrin toward human breast cancer cells. Life Sci 70(1): 49-56, 2001.

Singh RP, Agarwal C, et al. Inositol hexaphos-phate inhibits growth, and induces G1 arrest and apoptotic death of prostate carcinoma DU145 cells: modulation of CDKI-CDK-cyclin and pRb-related protein-E2F complexes. Carcinogenesis 24(3): 555-63, 2003.

Sliva D, Sedlak M, et al. Biologic activity of spores and dried powder from Ganoderma lucidum for the inhibition of highly invasive human Breast and prostate cancer cells. J Altern Complement Med 9(4): 491-7, 2003.

Strum S, Scholz M, et al. Modified Citrus Pectin Slows PSA Doubling Time: A Pilot Clinical Trial. International Conference on Diet and Prevention of Cancer, Tampere, Finland, 1999.

Weiss T, McCulloch M, et al. Modified Citrus Pec-tin Induces Cytotoxicity of Prostate Cancer Cells in Co-cultures with Human Endothelial Mono-layers. International Conference on Diet and Prevention of Cancer, Tampere, Finland. 1999.

Yan J, Katz AE. ProstaCaid induces G2/M cell cycle arrest and apoptosis in human and mouse androgen-dependent and-independent prostate cancer cells. Integr Cancer Ther. Jun;9(2):186-96, 2010.

Yan J, Katz A. PectaSol-C modified citrus pectin induces apoptosis and inhibition of proliferation in human and mouse androgen-dependent and- independent prostate cancer cells. Integr Cancer Ther. Jun;9(2):197-203, 2010.

Yu L, Blackburn GL, et al. Genistein and daidzein downregulate prostate androgen-regulated transcript-1 (PART-1) gene expression induced by dihydrotestosterone in human prostate LNCaP cancer cells. J Nutr 133(2): 389-92, 2003.

Zhou JR, Yu L, et al. Soy phytochemicals and tea bioactive components synergistically inhibit androgen-sensitive human prostate tumors in mice. J Nutr 133(2): 516-21, 2003.

Zhou JR, Yu L, et al. Inhibition of orthotopic growth and metastasis of androgen-sensitive human prostate tumors in mice by bioactive soybean components. Prostate 53(2): 143-53, 2003.

ABOUT THE AUTHOR

ISAAC ELIAZ, MD, MS, LAc

Dr. Isaac Eliaz, a pioneer in the field of integrative medicine since the early 1980’s, is a respected

author, lecturer, researcher, product formulator, and clinical practitioner.

Dr. Eliaz is a frequent guest lecturer on integrative medical approaches to health, immune en-

hancement, and cancer prevention and treatment. He has also taught several courses on Tradi-

tional Chinese Medicine for medical doctors and licensed acupuncturists. As an innovative formu-

lator of dietary supplements, Dr. Eliaz developed and currently holds the patents for several of his

unique herbal formulations. Many of these products are available through ecoNugenics, Inc., as

well as from leading integrative medical professionals.

To substantiate nutritional approaches to health, Dr. Eliaz regularly participates in clinical studies and has been published in well-

recognized, peer-reviewed journals. Also, many of Dr. Eliaz’ formulations have been submitted for validation in independent hu-

man clinical studies whose results have been published in peer-reviewed journals.

Dr. Eliaz continually studies, integrates, and applies the best of health practices of both western medicine and complementary

and alternative approaches. A native of Israel, Dr. Eliaz, lived in the Far East and Latin America before returning to study medicine

at Tel Aviv University. While studying for his degree, Dr. Eliaz’ interest turned towards the role of alternative therapies in daily health.

This led to his future research and personal experience with yoga, shiatsu, and acupuncture as therapeutic modalities.

After graduating from medical school in 1986, Dr. Eliaz established a highly successful clinical practice in Tel Aviv, utilizing his

training in both western and eastern medicine. While maintaining a clinical practice, Dr. Eliaz pursued graduate studies in clinical

herbology at the Hebrew University of Jerusalem and classical Chinese medicine with teachers in Israel and Europe.

In 1989 Dr. Eliaz moved to the San Francisco Bay area to continue his studies at the American College of Traditional Chinese

Medicine, earning a Master of Science degree in 1991. During this time, he also energetically sought-out leading practitioners

of alternative medicine to broaden his knowledge and experience. Since 1991 Dr. Eliaz has maintained a busy private practice in

Northern California that focuses primarily on integrative, holistic protocols for cancer patients.

The guiding mission of Dr. Eliaz’ professional life is achieving the integration and synergy of multiple healing modalities from both

ancient and modern paradigms into a holistic practice of medicine. It is the heart of his clinical practice, of his research, and a

mission that he communicates with great passion and clarity.


LEARN MORE

VISIT WWW.DRELIAZ.ORG TO REGISTER FOR MORE INFORMATION TODAY!

©2020 Dr. Isaac Eliaz, All rights reserved.
https://www.dreliaz.org/https://www.econugenics.com/https://www.dreliaz.org/

integrative approaches to prostate cancer treatment · 2020. 8. 11. · i’ll be covering a wide...

Documents